Clinical trials: Placebo Group
Asthma
Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients
The objective of this study is to assess the efficacy and safety of SOTB07 in asthma patients by observing changes FEV1 (% predicted) as the primary efficacy endpoint after oral administration of SOTB07 200mg, 400mg, placebo for…
- Trial name
- NCT01907763
- Testing
- SOTB07 200mg, SOTB07 400mg
- Where
- South Korea
- Volunteers
- 194 people
- Sponsor
- SK Chemicals Co., Ltd.
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.
- Trial name
- NCT00826514
- Testing
- Tanezumab
- Where
- 44 sites in United States, Canada and 3 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD)
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT06836063
- Testing
- Ropanicant
- Where
- 35 sites in United States
- Volunteers
- 214 people
- Sponsor
- Suven Life Sciences Limited
Postmenopausal Osteoporosis
Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk
A randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial to compare the efficacy and safety of QL1206 and placebo in postmenopausal women with osteoporosis at high risk of fracture
- Trial name
- NCT04128163
- Testing
- QL1206
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Fibromyalgia Syndrome, Primary
Fibromyalgia Study In Adults
A study to investigate ropinirole for treatment of the symptoms of fibromyalgia and in particular the widespread pain associated with this condition.
- Trial name
- NCT00256893
- Testing
- ropinirole
- Where
- 22 sites in Belgium, Denmark and 7 more
- Volunteers
- 164 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)
To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg daily versus ezetimibe placebo added daily to ongoing treatment with atorvastatin 10 mg daily in reducing the concentration of…
- Trial name
- NCT00651404
- Testing
- Ezetimibe
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Healthy
This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated
The main objective of this trial is to investigate the safety and tolerability of BI 730357 in Japanese healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03793621
- Testing
- BI 730357
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Narcolepsy
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.
- Trial name
- NCT02348593
- Testing
- JZP-110
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 239 people
- Sponsor
- Jazz Pharmaceuticals
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of…
- Trial name
- NCT01545076
- Testing
- IgPro20 (low dose), IgPro10, IgPro20 (high dose)
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 208 people
- Sponsor
- CSL Behring
Obesity
To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake
The purpose of this study is to evaluate the effect of lorcaserin on energy metabolism and food intake in obese and overweight patients.
- Trial name
- TULIP (NCT00829140)
- Testing
- Lorcaserin 10mg BID
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Eisai Inc.
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, T2DM
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
- Trial name
- NCT07527650
- Testing
- HM15275
- Where
- 20 sites in United States
- Volunteers
- 180 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Chronic Obstructive Pulmonary Disease (COPD)
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD
- Trial name
- NCT00703391
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Menopausal and Female Climacteric States
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.
- Trial name
- NCT00604825
- Testing
- GSK232802, PREMARIN
- Where
- 87 sites in United States, Argentina and 7 more
- Volunteers
- 356 people
- Sponsor
- GlaxoSmithKline
HCV Infection
Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection
This is a Phase 2b, randomized, double-blind, parallel-group, placebo-controlled, multicenter study investigating the safety, tolerability and efficacy of two oral doses of GS-9450 in adults with chronic Hepatitis C Virus (HCV).
- Trial name
- NCT00874796
- Testing
- GS-9450
- Where
- 73 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Gilead Sciences
Bilateral Nasal Polyposis
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects…
- Trial name
- NCT01624662
- Testing
- Fluticasone propionate
- Where
- 10 sites in United States
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Respiratory Distress Syndrome
Carperitide in Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study is to determine whether Carperitide is safe and effective in the management of Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT00030121
- Testing
- recombinant human atrial natriuretic polypeptide
- Sponsor
- Suntory Pharmaceutical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.